13 January 2021 - - US-based cancer genomics company Personal Genome Diagnostics Inc has entered into a collaboration with diagnostics company Qiagen to provide comprehensive genomic profiling tests and clinical decision support to molecular labs, the company said.

Under the non-exclusive agreement, PGDx will be responsible for the distribution of the PGDx elio™ oncology products and kitted solutions. Laboratories that purchase the PGDx elio products will have an option to receive from QIAGEN standardized reporting, driven by professional guidelines for streamlined case review and sign-out.

In addition, laboratories will receive access to QIAGEN's QCI Interpret One for rapid, evidence-based reporting for next-generation sequencing oncology tests at scale. Advancing cancer diagnostics and making precision medicine more accessible to healthcare systems, laboratories, and patients worldwide is a key focus of both parties.

Cancer guidelines increasingly call for comprehensive molecular profiling to optimize treatment planning and inform care.

PGDx elio tissue complete, the first FDA-cleared comprehensive genomic profiling kit, is used to identify alterations in the tumor and inform treatment decisions for patients with advanced solid tumors.

QCI Interpret One enables clinical labs to deliver oncologist-ready variant interpretation reports from NGS tests faster and with greater precision than ever before.

The kitted PGDx system allows molecular laboratories anywhere to perform this advanced genomic testing of cancer in a more efficient, standardized, and accurate manner.

By providing tests and interpretation support that can be run locally and automating the data analysis process, PGDx and QIAGEN are enabling the adoption of precision medicine in healthcare systems across the country, no matter where a patient seeks treatment.